Century Therapeutics targets CNTY-813 IND filing in Q4 2026, sees initial trial data in 2H 2027
IPSC•Century Therapeutics outlined nonclinical results for its CNTY-813 cell therapy and maintained its target for an IND filing in Q4 2026, with initial clinical data expected in the second half of 2027.
1. Preclinical findings and timeline
At EASD 2026, Century Therapeutics presented nonclinical results for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes. Animal studies showed durable blood-sugar control until graft removal, while manufacturing updates indicated consistent clinical-scale production; the company kept its target for an IND filing in Q4 2026 and expects initial clinical data in the second half of 2027.
